• Galderma Laboratories LP, of Fort Worth, Texas, said the FDA approved Mirvaso (brimonidine) topical gel 0.33 percent for the topical treatment of the facial erythema of rosacea in adults. Read More
• Arena Pharmaceuticals Inc., of San Diego, filed an 8-K with the SEC amending data released for its Phase Ib study of APD811, an oral prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension, to include reports of a serious adverse event. Read More
• Helix Biopharma Corp., of Aurora, Ontario, said it established a Polish subsidiary, Helix Polska, to facilitate and support ongoing clinical oncology research at leading research institutions in Poland. Read More
Zealand Pharma A/S added Eli Lilly and Co. to its roster of big pharma diabetes partners, entering a research collaboration with the Indianapolis-based firm that could eventually lead to a novel, first-in-class therapy. Read More
The FDA is investigating an incidence of a rare brain infection in a European patient who developed progressive multifocal leukoencephalopathy (PML) after receiving Novartis AG’s multiple sclerosis (MS) drug Gilenya (fingolimod). Read More
Abbvie Inc. launched the second pivotal Phase III trial of elagolix in endometriosis, moving Neurocrine Biosciences Inc. one step closer to key catalysts for its product development pipeline. The 24-week, multinational, randomized, double-blind, placebo-controlled study is almost identical in design to the initial Phase III, with both evaluating safety and efficacy in premenopausal women with moderate to severe pain associated with endometriosis. Read More
SHANGHAI – Four multinational pharmaceutical firms have been hit with allegations of bribery in China since the Glaxosmithkline plc scandal first broke almost two months ago. China’s State Administration for Industry & Commerce (SAIC) has announced a three-month probe that will target pharmaceutical and medical device sales. Read More
• Pfizer Inc., of New York, said it completed pneumonia case accrual in the CAPiTA (Community-Acquired Pneumonia Immunization Trial in Adults) 65 years and older. Read More
